Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases
Open accessThe DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Abstract
Maintenance of healthy human metabolism depends on a symbiotic consortium among bacteria, archaea, viruses, fungi, and host eukaryotic cells throughout the human gastrointestinal tract. Microbial communities provide the enzymatic machinery and the metabolic pathways that contribute to food digestion, xenobiotic metabolism, and production of a variety of bioactive molecules. These include vitamins, amino acids, short-chain fatty acids (SCFAs), and metabolites, which are essential for the interconnected pathways of glycolysis, the tricarboxylic acid/Krebs cycle, oxidative phosphorylation (OXPHOS), and amino acid and fatty acid metabolism. Recent studies have been elucidating how nutrients that fuel the metabolic processes impact on the ways immune cells, in particular, macrophages, respond to different stimuli under physiological and pathological conditions and become activated and acquire a specialized function. The two major inflammatory phenotypes of macrophages are controlled through differential consumption of glucose, glutamine, and oxygen. M1 phenotype is triggered by polarization signal from bacterial lipopolysaccharide (LPS) and Th1 proinflammatory cytokines such as interferon-γ, TNF-α, and IL-1 β, or both, whereas M2 phenotype is triggered by Th2 cytokines such as interleukin-4 and interleukin-13 as well as anti-inflammatory cytokines, IL-10 and TGF β, or glucocorticoids. Glucose utilization and production of chemical mediators including ATP, reactive oxygen species (ROS), nitric oxide (NO), and NADPH support effector activities of M1 macrophages. Dysbiosis is an imbalance of commensal and pathogenic bacteria and the production of microbial antigens and metabolites. It is now known that the gut microbiota-derived products induce low-grade inflammatory activation of tissue-resident macrophages and contribute to metabolic and degenerative diseases, including diabetes, obesity, metabolic syndrome, and cancer. Here, we update the potential interplay of host gut microbiome dysbiosis and metabolic diseases. We also summarize on advances on fecal therapy, probiotics, prebiotics, symbiotics, and nutrients and small molecule inhibitors of metabolic pathway enzymes as prophylactic and therapeutic agents for metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to regulation of infection and commensal spread, microbiome-immune interactions are implicated in a variety of ‘non-communicable’ gastrointestinal diseases including inflammatory bowel disease (IBD)8 and celiac diseases,9 as well as extra-intestinal disorders ranging from rheumatic arthritis,10 metabolic syndrome,11 neurodegenerative disorder12 to malignancy.13”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [11]
In the citing paper
“Changes in this microbial equilibrium that is, dysbiosis can promote and influence the course of many intestinal and extra-intestinal diseases[14-16].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 2×
“Several important questions on the complex interaction between host and microbes in pathophysiology of obesity remain answered [49, 74, 75].”
BackgroundA human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823 · cited 2×
“Several important questions on the complex interaction between host and microbes in pathophysiology of obesity remain answered [49, 74, 75].”
BackgroundEnterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 2×
“Unstimulated macrophages displaying M0 phenotype and exhibiting the differentiation surface markers CD68/ CD80//CD206 acquire and display the M1 phenotype (CD68/CD80//CD206) or M2 phenotype (CD68/ CD80/CD206/) after switching their metabolism and function in response to stimuli or polarization signals that initiate a…”
BackgroundThe gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 1×
“Initial clues for the role of microorganisms in energy homeostasis and obesity appeared from the studies using germ-free animals [76].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“A collection of 100-400× 10(12) of bacteria inhabits and lives in mutualistic relationships in the human GI tract [3].”
BackgroundMiller, M. B., & Bassler, B. L. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.165 · Cited by 5,105 · cited 1×
“Finally, bacteria can inhibit the growth of their competitors by long distance microbial communication, via release of metabolites and quorum sensing peptides, which are considered a biological strategy for maintenance of density of commensal species, and elimination of pathogenic bacteria [23, 24].”
Background
Cited by
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
The gut microbiota in anxiety and depression—A systematic review
Simpson, C. A., Diaz-Arteche, C., Eliby, D., Schwartz, O. S., Simmons, J. G., & Cowan, C. S. M. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101943 · Cited by 912
Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
Bruno, G., Zaccari, P., Rocco, G., Scalese, G., Panetta, C., Porowska, B., Pontone, S., & Severi, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i22.2706 · Cited by 258
Effects of Virgin Micro- and Nanoplastics on Fish: Trends, Meta-Analysis, and Perspectives
Jacob, H., Besson, M., Swarzenski, P. W., Lecchini, D., & Metian, M. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.9b05995 · Cited by 248
Tegegne, B. A., & Kebede, B. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09725 · Cited by 232
“Lacticaseibacillus rhamnosus, when mixed with Lactobacillus gasseri and Bifidobacterium lactis, has been demonstrated to inhibit weight gain in humans, specifically fat tissue mass adiposity, which strengthens the efficacy of probiotics in diabetes [91, 92].”
Background
Metadata
- Authors
- Belizário, J. E., Faintuch, J., & Garay-Malpartida, M.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Belizário, José E.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2018-12-09
- Volume
- 2018
- Pages
- 1-12
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC6304917
- OpenAlex
- W2904076340
- Cited by
- 341
- References
- 101
- Citations by year
- 2026: 27 · 2025: 34 · 2024: 55 · 2023: 46 · 2022: 64 · 2021: 47 · 2020: 51 · 2019: 17
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/18647-6, 2007/04513-1, 312206/2016-0, 308794/2014-1, 2011/188-37)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (2015/18647-6, 2007/04513-1, 312206/2016-0, 308794/2014-1, 2011/188-37)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (2015/18647-6, 2007/04513-1, 312206/2016-0, 308794/2014-1, 2011/188-37)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- gut dysbiosis, immunometabolism, macrophage polarization, M1/M2 macrophages, short-chain fatty acids, microbial metabolites, low-grade inflammation, metabolic disorders, obesity, diabetes mellitus, metabolic syndrome, cancer, fecal microbiota transplantation, probiotics, prebiotics, symbiotics, small molecule inhibitors, host-microbe interactions
- MeSH terms
- Gastrointestinal Microbiome, Animals, Humans, Macrophages, Metabolic Diseases, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. https://app.cochat.ai/papers/10.1155/2018/2037838
- The paper
- Belizário, J. E., Faintuch, J., & Garay-Malpartida, M. (2018). Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Mediators of Inflammation. https://doi.org/10.1155/2018/2037838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.